Overview

This trial is active, not recruiting.

Conditions coronary artery bypass grafting, heart diseases, heart valve diseases
Sponsor Weill Medical College of Cornell University
Start date January 2000
End date September 2007
Trial size 200 participants
Trial identifier NCT00226265, 1203-069

Summary

The purpose of this study is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Cardiac surgery patients who are between the ages of 18 and 100 - Are English speaking - Able to give consent - Undergoing cardiac surgery including (but not limited to): - Aortic valve replacement (AVR) - Mitral valve replacement (MVR) - Tricuspid valve replacement (TVR) - Coronary artery bypass graft (CABG). Exclusion Criteria: - Non-cardiac surgery patients

Additional Information

Official title The Short Form-36: Pre-vs. Post-Surgical Administration in Cardiac Surgery Patients
Principal investigator Mary E Charlson, MD
Description The purpose of this study, is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.
Trial information was received from ClinicalTrials.gov and was last updated in March 2008.
Information provided to ClinicalTrials.gov by Weill Medical College of Cornell University.